Compound to enhance immune stimulation
Year
2007
Project team
Gerald Fink and Ifat Rubin-Bejerano
![](https://deshpande.mit.edu/wp-content/uploads/2022/01/image204-aspect-ratio-580-360-580x360-c-default.jpg)
Potential of monoclonal antibodies
Monoclonal antibodies, currently a means of enabling speedier and more economic drug development, also have enormous untapped potential for use in more direct therapeutic applications for a wide range of diseases and conditions. However, many monoclonal antibodies currently fail to elicit an effective immune response, despite great specificity to target cells. This project is developing a compound to stimulate a more powerful immune response to specific monoclonal antibodies, potentially enabling development of effective new disease therapies.
![](https://live-mit-deshpande.pantheonsite.io/wp-content/uploads/2021/12/ImmuneXcite.jpg)
ImmuneXcite
The technology from this project was spun out into a startup company, ImmuneXcite.